Masao Hashimoto

7PUBLICATIONS
51CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 15, 2026
Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T-cell responses during chronic viral infection.

|Jan 08, 2025
An early precursor CD8+ T cell that adapts to acute or chronic viral infection.

Daniel T McManus, Rajesh M Valanparambil, Christopher B Medina

|Nov 22, 2023
Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade.

Annapaola Mariniello, Tahseen H Nasti, Daniel Y Chang

|Aug 25, 2023
PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors.

Amanda L Gill, Peter H Wang, Judong Lee

|Apr 07, 2023
Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition.

Laura Codarri Deak, Masao Hashimoto, Pablo Umaña

|Sep 28, 2022
PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program.

Masao Hashimoto, Koichi Araki, Maria A Cardenas

Pageof 2

Frequent Collaborators

6 joint publications

Rafi Ahmed

4 joint publications

Judong Lee

4 joint publications

Haydn T Kissick

4 joint publications

Pablo Umaña